NCT01477489View on ClinicalTrials.gov

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2017

Conditions
Breast Cancer
Interventions
DRUG

Veliparib

Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.

RADIATION

Standard radiation treatment

Limited to 60 Gy.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

27710

Duke, Durham

48109

University of Michigan, Ann Arbor

77030

MD Anderson Cancer Center, Houston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT01477489 - Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer | Biotech Hunter | Biotech Hunter